"In the study, 69 patients with cutaneous T-cell lymphoma, including the most common subtypes mycosis fungoides and Sézary syndrome, were given DD-cxdl for five consecutive days every 21 days. Roughly 36 percent of patients responded to the treatment, with more than 8 percent achieving a complete response. Study participants showed a median duration of response of more than eight months, and over 80 percent experienced a decrease in skin tumor burden."
"Currently, most treatments for cutaneous T-cell lymphoma do not produce long-lasting benefits. Many of these patients are middle-aged, so their life expectancy otherwise would be 20 to 30 years, but the duration of response for most treatments is only 12 to 14 months, leading to relapses and ultimately death."
Collection
[
|
...
]